Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUEST: Lifestyle Counseling and Medication for Adolescent Weight Management
NCT04873245Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- Mar 2022
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by University of Minnesota. Primary endpoint: Change in body mass index at 56 weeks. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04873245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873245.